BDX

BDX

Becton Dickinson

Dividend / Cash flow

★ Quality 19/100
Overvalued

Price today

$184.74

This company value is already calculated

We know what it is worth from its audited numbers, and whether it trades above or below that today. Create your free account to see it.

See what it is worth

charlieapp.co

What this business is made of

19qualityReturnsMoatBalance sheetPricing powerReinvestment

The business

The needle every hospital re-orders every week.

Becton Dickinson makes the boring, essential stuff of medicine: syringes, catheters, infusion systems, and diagnostics. It sells $21.8B a year, mostly single-use consumables the hospital re-orders every week. Gross margin is 45% and it generates $2.7B in free cash flow.

The moat lives in switching costs and regulation. A hospital won't redesign its protocols or recertify suppliers to save pennies on a needle. Scale and the distribution network help, but it's not a monopoly: it competes against capable players.

Revenue history

$20.2B
2021
$18.9B
2022
$19.4B
2023
$20.2B
2024
$21.8B
2025
CAGR 5 años: +2%

From $20.2B to $21.8B in 4 years. The business grows steadily.

Where each $100 of sales goes

Revenue $21.8B · FY2025

Cost of sales$11.9B · 55%
Operations$7.3B · 34%
Taxes and other$901M · 4%
Net profit$1.7B · 8%

Of every $100 in sales, $92 goes to costs and operations; $8 is left as net profit (8% margin).

Catalysts and risks

Spin-off of the Biosciences and Diagnostics business announced for late 2026, aiming to unlock value.

Paying down the $17.6B in debt with the $2.7B annual FCF improves the multiple.

Over 50 consecutive years raising the dividend — a Dividend King that keeps lifting the payout.

⚠️

$17.6B in debt against only $0.6B in cash: little room for mistakes.

⚠️

Revenue growth of 3%: this horse doesn't run, it trots.

⚠️

Hospital pricing pressure and exposure to FDA regulatory recalls.

Charlie's note

Paying 10.69x for a medical-consumables business that gets re-ordered every week, with a 45% gross margin and a real switching-cost moat, is buying quality at a sensible price; the 3% growth calls for patience, not euphoria.

Analysis · June 2026

Want to follow Becton Dickinson?

We do not calculate a value here: Becton Dickinson does not generate cash flows you can project, and putting a number on it would be making it up. What you can do is follow it and tell us the price you care about — we will email you when it gets there.

🔔 Email me

Free · no card

Charlie informs, it doesn't advise. No information should be taken as a recommendation to buy or sell.